A randomised, double-blind, placebo-controlled trial showed that recombinant interferon-gamma (rIFN-gamma) given by daily subcutaneous injection over 12 weeks in patients with moderate to severe atopic dermatitis was well tolerated and capable of producing significant clinical improvement. The gene discussed is IFNG; the disease is atopic eczema.